Presentation is loading. Please wait.

Presentation is loading. Please wait.

CPI-444 enhances T-cell activation in MC38 tumors.

Published byMateusz Kozak Modified over 4 years ago

Similar presentations

Presentation on theme: "CPI-444 enhances T-cell activation in MC38 tumors."— Presentation transcript:

1 CPI-444 enhances T-cell activation in MC38 tumors.
CPI-444 enhances T-cell activation in MC38 tumors. A, T-cell infiltration into MC38 tumors is increased following treatment with CPI-444 in combination with anti–PD-L1. Data were gated on CD45+ cells. B, IFNγ production in CD8+ T cells is increased by CPI-444 alone and in combination with anti–PD-L1. C, CPI-444 and anti–PD-L1 increase GITR expression on CD45+CD3+ T cells. D, CPI-444 increases the frequency IL7R expression on CD4+ T cells. E, Increased frequency of CD8+PD-1+ splenocytes in CPI-444 plus anti–PD-L1–treated mice is associated with smaller tumors. F, CPI-444 increases the frequency of CD8+Lag3+ T cells. Data were gated on the CD45+CD3+ population in the spleen. Significance was calculated using t tests (*, P < 0.05; **, P < 0.01; ***, P < 0.001). Each symbol represents an individual mouse tumor or spleen in all data plots. CPI-444 (100 mg/kg) and anti–PD-L1 (200 μg) were used in all experiments shown here. Stephen B. Willingham et al. Cancer Immunol Res 2018;6: ©2018 by American Association for Cancer Research

Download ppt "CPI-444 enhances T-cell activation in MC38 tumors."

Similar presentations

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.
Identification of combination treatment–responsive effector/memory tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Identification of combination treatment–responsive effector/memory tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.
Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.
Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs
Sunitinib plus rMVA–CEA–TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma.

Sunitinib plus rMVA–CEA–TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma.
Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.

Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.
Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
H31m1-PDL1 cells form progressively growing tumors in WT mice.

H31m1-PDL1 cells form progressively growing tumors in WT mice.
Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.

Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.
Cetuximab treatment increases IFNγ receptor 1 expression.

Cetuximab treatment increases IFNγ receptor 1 expression.
Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.
Anti–4-1BB/PD-1 combination enhanced antigen-specific T-cell response.

Anti–4-1BB/PD-1 combination enhanced antigen-specific T-cell response.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.
Administration of pIL2 and pgDE7 induces higher activation of E7-specific Tem CD8+ T cells. Administration of pIL2 and pgDE7 induces higher activation.

Administration of pIL2 and pgDE7 induces higher activation of E7-specific Tem CD8+ T cells. Administration of pIL2 and pgDE7 induces higher activation.
Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.
Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.
PD-1–PD-L1 axis is highly expressed and is not IFNγ-dependent in a subcutaneous murine model of PDA. A, experimental design for establishment of subcutaneous.

PD-1–PD-L1 axis is highly expressed and is not IFNγ-dependent in a subcutaneous murine model of PDA. A, experimental design for establishment of subcutaneous.
CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.
Quantification of MHC-I, β2m, and T-cell subsets.

Quantification of MHC-I, β2m, and T-cell subsets.

Similar presentations

Ads by Google